Translator Disclaimer
Paper
13 July 2009 A study of MRI-guided diffuse fluorescence molecular tomography for monitoring PDT effects in pancreas cancer
Author Affiliations +
Proceedings Volume 7380, Photodynamic Therapy: Back to the Future; 73803M (2009) https://doi.org/10.1117/12.823079
Event: 12th World Congress of the International Photodynamic Association, 2009, Seattle, Washington, United States
Abstract
Over the last several decades little progress has been made in the therapy and treatment monitoring of pancreas adenocarcinoma, a devastating and aggressive form of cancer that has a 5-year patient survival rate of 3%. Currently, investigations for the use of interstitial Verteporfin photodynamic therapy (PDT) are being undertaken in both orthotopic xenograft mouse models and in human clinical trials. In the mouse models, magnetic resonance (MR) imaging has been used as a measure of surrogate response to Verteporfin PDT; however, MR imaging alone lacks the molecular information required to assess the metabolic function and growth rates of the tumor immediately after treatment. We propose the implementation of MR-guided fluorescence tomography in conjunction with a fluorescently labeled (IR-Dye 800 CW, LI-COR) epidermal growth factor (EGF) as a molecular measure of surrogate response. To demonstrate the effectiveness of MR-guided diffuse fluorescence tomography for molecular imaging, we have used the AsPC-1 (+EGFR) human pancreatic adenocarcinoma in an orthotopic mouse model. EGF IRDye 800CW was injected 48 hours prior to imaging. MR image sequences were collected simultaneously with the fluorescence data using a MR-coupled diffuse optical tomography system. Image reconstruction was performed multiple times with varying abdominal organ segmentation in order to obtain a optimal tomographic image. It is shown that diffuse fluorescence tomography of the orthotopic pancreas model is feasible, with consideration of confounding fluorescence signals from the multiple organs and tissues surrounding the pancreas. MR-guided diffuse fluorescence tomography will be used to monitor EGF response after photodynamic therapy. Additionally, it provide the opportunity to individualize subsequent therapies based on response to PDT as well as to evaluate the success of combination therapies, such as PDT with chemotherapy, antibody therapy or even radiation.
© (2009) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Kimberley S. Samkoe, Scott C. Davis, Subhadra Srinivasan, Julia A. O'Hara, Tayyaba Hasan, and Brian W. Pogue "A study of MRI-guided diffuse fluorescence molecular tomography for monitoring PDT effects in pancreas cancer", Proc. SPIE 7380, Photodynamic Therapy: Back to the Future, 73803M (13 July 2009); https://doi.org/10.1117/12.823079
PROCEEDINGS
8 PAGES


SHARE
Advertisement
Advertisement
Back to Top